Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:PTGX NYSE:QGEN NASDAQ:SION On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$80.610.0%$83.31$28.06▼$103.00$6.63B2.06673,813 shs407,642 shsPTGXProtagonist Therapeutics$102.01+1.1%$101.13$45.14▼$107.84$6.56B1.89748,288 shs402,919 shsQGENQiagen$34.88-0.6%$38.46$32.53▼$57.81$7.19B0.642.33 million shs1.23 million shsSIONSionna Therapeutics$41.75+5.7%$39.56$12.42▼$48.44$1.89B1.35346,388 shs236,910 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics+3.21%-5.77%-7.22%-6.76%+156.52%PTGXProtagonist Therapeutics+2.55%-2.89%-4.35%+21.41%+116.43%QGENQiagen+2.33%+7.12%-14.68%-27.49%-22.02%SIONSionna Therapeutics+4.83%-8.40%-7.36%+5.78%+181.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$80.610.0%$83.31$28.06▼$103.00$6.63B2.06673,813 shs407,642 shsPTGXProtagonist Therapeutics$102.01+1.1%$101.13$45.14▼$107.84$6.56B1.89748,288 shs402,919 shsQGENQiagen$34.88-0.6%$38.46$32.53▼$57.81$7.19B0.642.33 million shs1.23 million shsSIONSionna Therapeutics$41.75+5.7%$39.56$12.42▼$48.44$1.89B1.35346,388 shs236,910 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics+3.21%-5.77%-7.22%-6.76%+156.52%PTGXProtagonist Therapeutics+2.55%-2.89%-4.35%+21.41%+116.43%QGENQiagen+2.33%+7.12%-14.68%-27.49%-22.02%SIONSionna Therapeutics+4.83%-8.40%-7.36%+5.78%+181.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.95Moderate Buy$118.1046.50% UpsidePTGXProtagonist Therapeutics 2.81Moderate Buy$115.2112.94% UpsideQGENQiagen 2.50Moderate Buy$44.9828.94% UpsideSIONSionna Therapeutics 2.85Moderate Buy$53.2227.48% UpsideCurrent Analyst Ratings BreakdownLatest SION, KYMR, QGEN, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/20/2026SIONSionna Therapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/18/2026SIONSionna Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $55.005/18/2026QGENQiagen Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$50.00 ➝ $36.005/18/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/13/2026SIONSionna Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$58.005/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/8/2026SIONSionna Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$39.21M169.11N/AN/A$18.72 per share4.31PTGXProtagonist Therapeutics$46.02M142.55N/AN/A$10.19 per share10.01QGENQiagen$2.09B3.44$3.47 per share10.06$16.17 per share2.16SIONSionna TherapeuticsN/AN/AN/AN/A$6.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/APTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)QGENQiagen$424.88M$1.9118.2213.113.4119.16%14.40%8.40%8/4/2026 (Estimated)SIONSionna Therapeutics-$75.27M-$1.93N/AN/AN/AN/A-27.31%-25.88%N/ALatest SION, KYMR, QGEN, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SIONSionna Therapeutics-$0.52-$0.60-$0.08-$0.60N/AN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/2/2026Q4 2025SIONSionna Therapeutics-$0.61-$0.46+$0.15-$0.46N/AN/A2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AQGENQiagen$0.260.75%N/A13.61%N/ASIONSionna TherapeuticsN/AN/AN/AN/AN/ALatest SION, KYMR, QGEN, and PTGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A10.8110.81PTGXProtagonist TherapeuticsN/A17.7617.76QGENQiagen0.493.212.57SIONSionna TherapeuticsN/A22.6022.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%QGENQiagen70.00%SIONSionna TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics15.98%PTGXProtagonist Therapeutics5.19%QGENQiagen9.00%SIONSionna Therapeutics3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableSIONSionna Therapeutics3545.15 million43.39 millionN/ASION, KYMR, QGEN, and PTGX HeadlinesRecent News About These CompaniesSionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by Freedom CapitalMay 21 at 6:10 AM | marketbeat.comFreedom Broker downgrades Sionna Therapeutics (SION)May 21 at 1:27 AM | msn.comLifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)May 17, 2026 | theglobeandmail.comSionna Therapeutics, Inc. $SION Shares Purchased by Vanguard Group Inc.May 16, 2026 | marketbeat.comSionna Therapeutics (NASDAQ:SION) Stock Rating Lowered by Wall Street ZenMay 16, 2026 | americanbankingnews.comSionna Therapeutics Inc SIONMay 15, 2026 | morningstar.comMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Verrica Pharmaceuticals (VRCA) and Arvinas Holding Company (ARVN)May 15, 2026 | theglobeandmail.comWedbush Remains a Buy on Sionna Therapeutics, Inc. (SION)May 15, 2026 | theglobeandmail.comSionna Therapeutics' (SION) "Buy" Rating Reaffirmed at BTIG ResearchMay 14, 2026 | americanbankingnews.comBTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION)May 13, 2026 | marketbeat.comSionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | globenewswire.comSionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing EarningsMay 12, 2026 | marketbeat.comSionna Therapeutics Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comSionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 184,639 Shares of StockMay 12, 2026 | americanbankingnews.comSionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 59,767 Shares of StockMay 12, 2026 | americanbankingnews.comSionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 48,546 Shares of StockMay 12, 2026 | americanbankingnews.comSionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 59,767 SharesMay 12, 2026 | americanbankingnews.comSionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 48,546 Shares of StockMay 12, 2026 | americanbankingnews.comSionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 184,639 Shares of StockMay 12, 2026 | americanbankingnews.comOrbimed Advisors Llc Sells 48,546 Shares of Sionna Therapeutics (NASDAQ:SION) StockMay 12, 2026 | insidertrades.comOrbimed Advisors Llc Sells 59,767 Shares of Sionna Therapeutics (NASDAQ:SION) StockMay 11, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 20261 Stock Is Powering the AI Boom and the Next Farm SupercycleBy Jeffrey Neal Johnson | April 22, 2026Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?By Ryan Hasson | May 12, 2026Tractor Supply’s 10% Culling: A Bruise, Not a BreakBy Jeffrey Neal Johnson | April 22, 2026Tesla’s Earnings Confirm the Shift to AI—But at What Cost?By Sam Quirke | April 23, 2026SION, KYMR, QGEN, and PTGX Company DescriptionsKymera Therapeutics NASDAQ:KYMR$80.61 -0.04 (-0.05%) Closing price 04:00 PM EasternExtended Trading$80.62 +0.01 (+0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$102.01 +1.13 (+1.12%) Closing price 04:00 PM EasternExtended Trading$105.00 +2.99 (+2.93%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Qiagen NYSE:QGEN$34.88 -0.21 (-0.59%) Closing price 03:59 PM EasternExtended Trading$34.90 +0.02 (+0.06%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Sionna Therapeutics NASDAQ:SION$41.75 +2.25 (+5.70%) Closing price 04:00 PM EasternExtended Trading$40.20 -1.55 (-3.70%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
